vadimezan

Known as: 5,6-dimethylxanthenone-4-acetic acid, 5,6-dimethyl xanthenone acetic acid, 5,6-MexXAA 
A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Spontaneous tumor-initiated T cell priming is dependent on IFN-β production by tumor-resident dendritic cells. On the basis of… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2012
2012
The chemotherapeutic agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a potent inducer of type I IFNs and other cytokines… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The macrophage proinflammatory response to Francisella tularensis (Ft) live vaccine strain (LVS) was shown previously to be TLR2… (More)
Is this relevant?
Review
2005
Review
2005
Low-molecular-weight vascular-disrupting agents (VDAs) cause a pronounced shutdown in blood flow to solid tumours, resulting in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The selective serotonergic neurotoxicity of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2004
Review
2004
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
The utility of combining the vascular targeting agents 5,6-dimethyl-xanthenone-4 acetic acid (DMXAA) and combretastatin A-4… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) causes vascular shutdown in preclinical models. Dynamic contrast-enhanced… (More)
Is this relevant?
1999
1999
The selective induction of tumor vascular collapse represents an exciting approach to cancer treatment. However, clinical… (More)
  • figure 1
  • figure 2
  • figure 5
  • figure 3
  • figure 4
Is this relevant?